Exozymes Inc. priced its initial public offering at $8.00 a share, to list on the Nasdaq Capital Market under the symbol EXOZ. It filed a Form S-1 registration statement for an initial public offering on November 6, 2026. As of November 8, 2026, its final prospectus is on file (Form 424B4, November 12, 2024).
Sell to companies like Exozymes Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Exozymes Inc. filed a Form S-1 registration statement for an initial public offering on 2026-11-06. It has amended it 5 times. It filed its final prospectus on 2024-11-12, at a public offering price of $8.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for Exozymes Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 19, 2024 | Form D, private offering | $12K sold | Form D page | Source |
Check before you invest in Exozymes Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Exozymes Inc. and the records around it.
Also filing to list on the Nasdaq Capital Market
IPO filings on the Nasdaq Capital Market in Q4 2026, newest first.
- AKANDA CORP. (Nov 2026)
- HomesToLife Ltd (Nov 2026)
- Fitness Champs Holdings Ltd (Nov 2026)
Watch Exozymes Inc.
Get an email when Exozymes Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Exozymes Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Exozymes Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Exozymes Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common stock is listed on The Nasdaq Capital Market under the symbol “EXOZ.” We do not intend to apply for listing of the purchase warrants on any national securities exchange or other nationally recognized trading system.From the S-1 filed 2026-11-06
Offering price
After giving effect to the receipt of the net proceeds from our sale of 1,875,000 shares of Common Stock in the offering at the public offering price of $8.00 per share of Common Stock, after deducting the full potential commissions and discounts and the estimated offering expenses payable by us of $522,253, not taking into account the fact that the underwriter may purchase some of the offered shares at the public offering price, without any discount and commission, our pro forma as adjusted net tangible book value as of June 30, 2024, would have been approximately $11,015,529, or $1.36 per share of Common Stock.From the 424B4 filed 2024-11-12
Use of proceeds
We intend to use the net proceeds from this offering to further develop the opportunities associated with our NCT business and products developed under the NCT technology, to advance our next-in-line product candidates, for research and development and for working capital and general corporate purposes, including capital expenditures.From the S-1 filed 2026-11-06
Revenue
in the case of an issuer whose public float as calculated under paragraph (1) or (2) of this definition was zero or whose public float was less than $700 million, had annual revenues of less than $100 million during the most recently completed fiscal year for which audited financial statements are available.From the S-1/A filed 2024-10-21
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-08-01 | Registration statement amended | S-1/A |
| 2024-09-06 | Registration statement amended | S-1/A |
| 2024-09-19 | Registration statement amended | S-1/A |
| 2024-10-04 | Registration statement amended | S-1/A |
| 2024-10-21 | Registration statement amended | S-1/A |
| 2024-11-12 | Final prospectus filed: the offering is priced | 424B4 |
| 2024-11-12 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-11-06 | Registration statement filed | S-1 |
Tools for this story
Each opens in a new tab, filled in for Exozymes Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.